Joyce Cheng

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Jennifer Gao, Joyce Cheng, Erik Bloomquist et al. · The Lancet Oncology · 2019 · 288 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +8

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Sandra J. Casak, Leigh Marcus, Lola A. Fashoyin‐Aje et al. · Clinical Cancer Research · 2021 · 167 citations · Full text

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood et al. · Clinical Cancer Research · 2020 · 142 citations

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Harpreet Singh, Amanda J. Walker, Laleh Amiri‐Kordestani et al. · Clinical Cancer Research · 2018 · 96 citations · Full text

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Sonia Singh, Adnan A. Jaigirdar, Flora Mulkey et al. · Clinical Cancer Research · 2020 · 88 citations · Full text

Cancer Management, Pharmacotherapy, Metronomic Chemotherapy +16